164 related articles for article (PubMed ID: 16889755)
1. The immunomodulator AS101 induces growth arrest and apoptosis in multiple myeloma: association with the Akt/survivin pathway.
Hayun M; Naor Y; Weil M; Albeck M; Peled A; Don J; Haran-Ghera N; Sredni B
Biochem Pharmacol; 2006 Nov; 72(11):1423-31. PubMed ID: 16889755
[TBL] [Abstract][Full Text] [Related]
2. Induction therapy in a multiple myeloma mouse model using a combination of AS101 and melphalan, and the activity of AS101 in a tumor microenvironment model.
Hayun M; Saida H; Albeck M; Peled A; Haran-Ghera N; Sredni B
Exp Hematol; 2009 May; 37(5):593-603. PubMed ID: 19375650
[TBL] [Abstract][Full Text] [Related]
3. Sensitizing B- and T- cell Lymphoma Cells to Paclitaxel/Abraxane-Induced Death by AS101 via Inhibition of the VLA-4-IL10-Survivin Axis.
Danoch H; Kalechman Y; Albeck M; Longo DL; Sredni B
Mol Cancer Res; 2015 Mar; 13(3):411-22. PubMed ID: 25351768
[TBL] [Abstract][Full Text] [Related]
4. Multiple signal transduction pathways are involved in G2/M growth arrest and apoptosis induced by the immunomodulator AS101 in multiple myeloma.
Naor Y; Hayun M; Sredni B; Don J
Leuk Lymphoma; 2013 Jan; 54(1):160-6. PubMed ID: 22712839
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation by ammonium trichloro(dioxoethylene-0,0') tellurate (AS101) of Fas/Apo-1 expression on B16 melanoma cells: implications for the antitumor effects of AS101.
Kalechman Y; Strassmann G; Albeck M; Sredni B
J Immunol; 1998 Oct; 161(7):3536-42. PubMed ID: 9759874
[TBL] [Abstract][Full Text] [Related]
6. Ammonium trichloro(dioxoethylene-o,o')tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop.
Sredni B; Weil M; Khomenok G; Lebenthal I; Teitz S; Mardor Y; Ram Z; Orenstein A; Kershenovich A; Michowiz S; Cohen YI; Rappaport ZH; Freidkin I; Albeck M; Longo DL; Kalechman Y
Cancer Res; 2004 Mar; 64(5):1843-52. PubMed ID: 14996748
[TBL] [Abstract][Full Text] [Related]
7. The protective role of ammonium trichloro(dioxoethylene-O,O')tellurate in combination with several cytotoxic drugs acting by different mechanisms of action.
Kalechman Y; Shani A; Sotnik-Barkai I; Albeck M; Sredni B
Cancer Res; 1993 Dec; 53(24):5962-9. PubMed ID: 8261410
[TBL] [Abstract][Full Text] [Related]
8. Multifunctional activity of a small tellurium redox immunomodulator compound, AS101, on dextran sodium sulfate-induced murine colitis.
Halpert G; Eitan T; Voronov E; Apte RN; Rath-Wolfson L; Albeck M; Kalechman Y; Sredni B
J Biol Chem; 2014 Jun; 289(24):17215-27. PubMed ID: 24764299
[TBL] [Abstract][Full Text] [Related]
9. Novel involvement of the immunomodulator AS101 in IL-10 signaling, via the tyrosine kinase Fer.
Hayun R; Shpungin S; Malovani H; Albeck M; Okun E; Nir U; Sredni B
Ann N Y Acad Sci; 2007 Jan; 1095():240-50. PubMed ID: 17404037
[TBL] [Abstract][Full Text] [Related]
10. Differential effect of the immunomodulator AS101 on B7-1 and B7-2 costimulatory molecules: role in the antitumoral effects of AS101.
Kalechman Y; Sredni B
J Immunol; 1996 Jul; 157(2):589-97. PubMed ID: 8752906
[TBL] [Abstract][Full Text] [Related]
11. Ammonium trichloro [1,2-ethanediolato-O,O']-tellurate cures experimental visceral leishmaniasis by redox modulation of Leishmania donovani trypanothione reductase and inhibiting host integrin linked PI3K/Akt pathway.
Vishwakarma P; Parmar N; Chandrakar P; Sharma T; Kathuria M; Agnihotri PK; Siddiqi MI; Mitra K; Kar S
Cell Mol Life Sci; 2018 Feb; 75(3):563-588. PubMed ID: 28900667
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of interleukin-10 by the immunomodulator AS101 reduces mesangial cell proliferation in experimental mesangioproliferative glomerulonephritis: association with dephosphorylation of STAT3.
Kalechman Y; Gafter U; Weinstein T; Chagnac A; Freidkin I; Tobar A; Albeck M; Sredni B
J Biol Chem; 2004 Jun; 279(23):24724-32. PubMed ID: 15001575
[TBL] [Abstract][Full Text] [Related]
13. Production of the novel mesangial autocrine growth factors GDNF and IL-10 is regulated by the immunomodulator AS101.
Kalechman Y; Sredni B; Weinstein T; Freidkin I; Tobar A; Albeck M; Gafter U
J Am Soc Nephrol; 2003 Mar; 14(3):620-30. PubMed ID: 12595497
[TBL] [Abstract][Full Text] [Related]
14. Antitumour effects in mycosis fungoides of the immunomodulatory, tellurium-based compound, AS101.
Frei GM; Kremer M; Hanschmann KM; Krause S; Albeck M; Sredni B; Schnierle BS
Br J Dermatol; 2008 Mar; 158(3):578-86. PubMed ID: 18241275
[TBL] [Abstract][Full Text] [Related]
15. The antitumoral effect of the immunomodulator AS101 and paclitaxel (Taxol) in a murine model of lung adenocarcinoma.
Kalechman Y; Shani A; Dovrat S; Whisnant JK; Mettinger K; Albeck M; Sredni B
J Immunol; 1996 Feb; 156(3):1101-9. PubMed ID: 8557985
[TBL] [Abstract][Full Text] [Related]
16. Neutral and positively charged thiols synergize the effect of the immunomodulator AS101 as a growth inhibitor of Jurkat cells, by increasing its uptake.
Frei GM; Lebenthal I; Albeck M; Albeck A; Sredni B
Biochem Pharmacol; 2007 Sep; 74(5):712-22. PubMed ID: 17632085
[TBL] [Abstract][Full Text] [Related]
17. Hair growth induction by the Tellurium immunomodulator AS101: association with delayed terminal differentiation of follicular keratinocytes and ras-dependent up-regulation of KGF expression.
Sredni B; Gal R; Cohen IJ; Dazard JE; Givol D; Gafter U; Motro B; Eliyahu S; Albeck M; Lander HM; Kalechman Y
FASEB J; 2004 Feb; 18(2):400-2. PubMed ID: 14656992
[TBL] [Abstract][Full Text] [Related]
18. Protective effect of the immunomodulator AS101 against cyclophosphamide-induced testicular damage in mice.
Carmely A; Meirow D; Peretz A; Albeck M; Bartoov B; Sredni B
Hum Reprod; 2009 Jun; 24(6):1322-9. PubMed ID: 19240057
[TBL] [Abstract][Full Text] [Related]
19. Effect of AS101 on bryostatin 1-mediated differentiation induction, cell cycle arrest, and modulation of drug-induced apoptosis in human myeloid leukemia cells.
Rao AS; Freemerman AJ; Jarvis WD; Chelliah J; Bear HD; Mikkelsen R; Grant S
Leukemia; 1996 Jul; 10(7):1150-8. PubMed ID: 8683995
[TBL] [Abstract][Full Text] [Related]
20. Increased DNA repair ability after irradiation following treatment with the immunomodulator AS101.
Kalechman Y; Shani A; Albeck M; Sotnik Barkai I; Sredni B
Radiat Res; 1993 Nov; 136(2):197-204. PubMed ID: 8248476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
